Project description
Proteosome structure and degradation landscape regulation in cancer
Proteasomes remove defective or obsolete proteins, playing a role in cell signalling and antigen presentation. Proteasomal degradation was implicated in tumour interaction with immunity, but a comprehensive analysis of significance in cancer is not complete. Researchers from the Weizmann Institute of Science in Israel developed proteasomal footprinting using mass spectrometry analysis of proteolytic peptides (MAPP) for capturing, isolation, and analysis of proteasome-cleaved peptides. The EU-funded Cancer_Deg project aims to further develop MAPP technology to uncover the critical role of degradation pathways in cancer. The objectives include the development of in vivo characterisation of proteasome composition and the degradation landscape in different cancers, the study of the mechanisms underlying tumour immunogenicity and response to immunotherapy, and the exploitation of inter-patient proteasome heterogeneity for translational purposes.
Objective
Proteasome activity is crucial to removal of defective or obsolete proteins, cell signaling and antigen presentation. In cancer, proteasomal degradation was shown to play key roles in tumor growth, antigenicity and response to immunotherapy. Yet, comprehensive analysis of proteasome subunit composition and the degradation landscape in cancer has not been performed to date, rendering our understanding of inter-patient proteasome heterogeneity and proteasome-dependent mechanisms underlying tumor-immune interactions far from complete.
Our novel, unbiased approach, MAPP, for MS Analysis of Proteasome-cleaved Peptides, is ideally suited to examine the missing link between cellular degradation and cancer immunity. We have already demonstrated its utility in identifying degradation events associated with inflammation, proteasome cleavage, substrate alterations and an anti-inflammatory role of the proteasome subunit PSME4, in lung cancer.
We aim to capitalize on our powerful analytical methods, vast experience and preliminary data and develop further our cutting-edge technology, to shed light on the uncharted area of degradation pathways in cancer. We plan to:
(1) Characterize both proteasome composition and the degradation landscape across cancer types and develop MAPP further to enable in vivo, tissue-specific, and proteasome-type-specific profiling. We strive to provide a near complete narrative of proteasome activity and distribution in tumors and their role in shaping tumor-immune interactions.
(2) Study proteasome-dependent mechanisms underlying tumor immunogenicity and response to immunotherapy at the biochemical, cellular and physiological levels.
(3) Exploit inter-patient proteasome heterogeneity for translational opportunities, in particular as an adjunct to current immunotherapies.
Cancer_Deg will transform our understanding of proteasomal degradation in cancer, with important implications for numerous diseases, precision oncology and drug discovery.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.
- natural sciences biological sciences biochemistry biomolecules proteins
- medical and health sciences clinical medicine oncology
- medical and health sciences basic medicine immunology immunotherapy
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Keywords
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
HORIZON.1.1 - European Research Council (ERC)
MAIN PROGRAMME
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
HORIZON-ERC - HORIZON ERC Grants
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) ERC-2021-COG
See all projects funded under this callHost institution
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
7610001 Rehovot
Israel
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.